(Q37184065)

18 August 2017

1 reference

title

Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system (English)

1 reference

18 August 2017

Theodore W Kurtz

1

1 reference

18 August 2017

Michal Pravenec

series ordinal

2

1 reference

18 August 2017

publication date

5 June 2008

1 reference

Journal of Clinical Hypertension

18 August 2017

published in

1 reference

18 August 2017

volume

21

1 reference

18 August 2017

issue

8

1 reference

18 August 2017

page(s)

852-859

1 reference

Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Uric acid reduction: a new paradigm in the management of cardiovascular risk?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Part 1. Uric acid and losartan

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Uric acid: role in cardiovascular disease and effects of losartan

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Cell biology of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Inhibition of platelet aggregability by losartan in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

https://api.crossref.org/works/10.1038%2FAJH.2008.202

1 reference

7 January 2021

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2008.202

7 January 2021

Identifiers

DOI

10.1038/AJH.2008.202

1 reference

18 August 2017

1 reference